Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLNNW 
Clene Inc (CLNNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CLNNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 646.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 |
52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5032.1% |
Management Effectiveness
Return on Assets (TTM) -49.62% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6140786 |
Shares Outstanding - | Shares Floating 6140786 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Clene Inc
Company Overview
History and Background
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing novel neurotherapeutic solutions for neurodegenerative diseases. Founded in 2012, Clene has focused on developing a novel nanotherapeutic platform based on catalytically-active gold nanocrystals.
Core Business Areas
- Neurodegenerative Disease Therapies: Clene's primary focus is on developing therapies for neurodegenerative diseases, with a lead candidate, CNM-Au8, targeting multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease.
- Nanocrystalline Gold Platform: Clene has developed a proprietary nanocrystalline gold platform that is designed to promote neuronal survival and function through improved cellular energy production and reduced oxidative stress.
Leadership and Structure
Rob Etherington serves as the President and CEO. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercialization strategy.
Top Products and Market Share
Key Offerings
- CNM-Au8: CNM-Au8 is Clene's lead therapeutic candidate, an oral suspension of gold nanocrystals designed to treat neurodegenerative diseases. As a clinical stage company it has not generated revenue, nor has a market share. Competitors include pharmaceutical companies developing treatments for MS, ALS and Parkinsons such as Biogen (BIIB), Novartis (NVS), and Teva (TEVA).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant investment in drug development. Focus areas include neurodegenerative diseases, driven by an aging population and unmet medical needs.
Positioning
Clene Inc. is positioned as an innovator in nanotherapeutics for neurodegenerative diseases. Competitive advantages include its novel gold nanocrystal platform and clinical data suggesting potential efficacy in MS, ALS, and Parkinson's.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is estimated to be in the tens of billions of dollars annually. Clene is positioned to capture a portion of this market with successful development and commercialization of CNM-Au8.
Upturn SWOT Analysis
Strengths
- Novel nanocrystalline gold platform
- Clinical data showing potential efficacy
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on successful clinical trial outcomes
- High regulatory hurdles for new drug approvals
- Uncertainty regarding commercial scalability
Opportunities
- Potential to address unmet medical needs in neurodegenerative diseases
- Partnerships with larger pharmaceutical companies
- Expansion of nanocrystal platform to other therapeutic areas
- Breakthrough Therapy designation and other regulatory advantages
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- TEVA
Competitive Landscape
Clene faces competition from established pharmaceutical companies with greater resources and approved therapies for neurodegenerative diseases. Clene's competitive advantage lies in its novel nanocrystalline gold platform and potential to address underlying disease mechanisms.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by progress in clinical trials and expansion of the pipeline.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of CNM-Au8.
Recent Initiatives: Recent initiatives include the ongoing clinical trials for CNM-Au8 in MS, ALS, and Parkinson's disease.
Summary
Clene Inc. is a clinical-stage biopharmaceutical company with a novel nanocrystalline gold platform and potential to revolutionize the treatment of neurodegenerative diseases. While there are limited financial resources and dependence on successful clinical trials, the company has strong IP and is attempting to solve some of the world's unmet medical needs. Investors must be aware of regulatory setbacks and the competitive landscape as well as high risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Clene Inc. SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.